Heather Getz Acquires 15,000 Shares of TELA Bio (NASDAQ:TELA) Stock

TELA Bio, Inc. (NASDAQ:TELA) CEO Heather Getz acquired 15,000 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $0.70 per share, for a total transaction of $10,500.00. Following the completion of the purchase, the chief executive officer directly owned 520,000 shares in the company, valued at $364,000. This trade represents a 2.97% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

TELA Bio Stock Down 1.1%

Shares of TELA Bio stock opened at $0.64 on Wednesday. The stock’s 50-day moving average is $0.77 and its 200 day moving average is $0.79. TELA Bio, Inc. has a one year low of $0.50 and a one year high of $2.00. The firm has a market cap of $28.87 million, a price-to-earnings ratio of -0.84 and a beta of 1.34. The company has a debt-to-equity ratio of 8.82, a current ratio of 2.99 and a quick ratio of 2.38.

TELA Bio (NASDAQ:TELA) last issued its earnings results on Monday, August 10th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $19.29 million during the quarter, compared to the consensus estimate of $20.01 million. TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 51.53%. Equities research analysts anticipate that TELA Bio, Inc. will post -0.76 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in TELA Bio in the fourth quarter worth approximately $48,000. Citadel Advisors LLC increased its holdings in shares of TELA Bio by 161.3% during the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock valued at $53,000 after acquiring an additional 21,781 shares in the last quarter. UP Strategic Wealth Investment Advisors LLC bought a new stake in shares of TELA Bio during the second quarter valued at approximately $91,000. Susquehanna International Group LLP raised its position in shares of TELA Bio by 551.2% during the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after purchasing an additional 72,594 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of TELA Bio by 101.4% during the fourth quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock worth $152,000 after purchasing an additional 64,800 shares during the period. 94.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, TELA Bio presently has a consensus rating of “Hold” and an average price target of $2.20.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial?stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.